Ischemia modified albumin as a useful marker for diagnoses and management of diabetic retinopathy

Ischemia modified albumin (IMA) may aid in the early detection and management of diabetic retinopathy (DR). In this study, we examined the relationship between IMA and DR, and the effect of intravitreal anti-vascular endothelial growth factor (anti-VEGF) on IMA levels in patients with DR. This Quasi...

Full description

Saved in:

Bibliographic Details
Published in:	Pakistan journal of medical sciences 2022-03, Vol.38 (4Part-II), p.1043-1047
Main Authors:	Kumar, Winay, Martins, Russell Seth, Anjum, Nargis, Fatima, Syeda Sadia
Format:	Article
Language:	eng
Subjects:	Age Albumin Biomarkers Blood pressure Body mass index Care and treatment Cholesterol Diabetes Diabetic retinopathy Edema Fasting Glucose Ischemia Original Oxidative stress Povidone Type 2 diabetes Vascular endothelial growth factor
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Ischemia modified albumin (IMA) may aid in the early detection and management of diabetic retinopathy (DR). In this study, we examined the relationship between IMA and DR, and the effect of intravitreal anti-vascular endothelial growth factor (anti-VEGF) on IMA levels in patients with DR. This Quasi-experimental study was conducted from March-December 2018 at a Al-Ibrahim Eye Hospital in Karachi, Pakistan. Adult patients (age ≥ 18 year) with Type-2 diabetes mellitus (T2DM) presenting to the Diabetic Clinic were categorized as control (Group-A n=30: DM without DR) or case (Group-B n=59: DM with DR). Patients in Group-B received an intravitreal injection of bevacizumab (anti-VEGF). Visual acuity, retinoscopy and serum IMA were recorded at baseline and at a 30-day follow-up for both groups. A significant drop in IMA levels was seen one month after bevacizumab (IMA baseline: 1590.82±121.22 and follow up: 940.8±91.26; p
ISSN:	1682-024X 1681-715X